Kymera Investor Day Presentation Deck

• No SAEs • Treatment-related AEs were self-limiting and resolved • No ECG changes, including QTc KYMERA Blinded MAD Safety Summary n=12 per cohort (9 drug/3 placebo) ©2021 KYMERA THERAPEUTICS, INC. Possibly or Probably Treatment-Related AES* (>1 Subject) #Subjects ** AEs Headache Palpitations** Nausea 6 KYMERA R&D DAY - December 16th, 2021 3 2 Severity Moderate, Mild Mild Mild (x3) Mild (x3) Mild (x2) Cohort MAD2 per investigator assessment; all were considered possibly-related, single, transient self-reported episodes during 21 days of in-patient observation in Phase 1 unit; not associated with any objective findings and did not lead to interruption in dosing MAD 3 MAD 4 MAD 2, MAD 4 (x2) MAD 2 PAGE 41

View entire presentation